Old news but good article.
“The encouraging results of our phase I study with Zantrene monotherapy and the current phase II study with Zantrene in high-risk, advanced AML patients are encouraging and may indicate a role for Zantrene in the modern AML treatment paradigm to the benefit of our patients,” said Prof. Arnon Nagler.
Sheba’s researchers are optimistic that patients will continue to respond favorably to Zantrene as the trial progresses, reporting results as they are analyzed over the study period so that the treatment can be approved for integration into regular clinical use as
https://www.shebaonline.org/zantrene-may-promote-long-term-remission-in-acute-myeloid-leukemia-patients-sheba-study-indicates/?__cf_chl_tk=B3dnjDzUQvWyoa.iRyNB8Nhi1BdccbITjBEjUvtet7g-1719110136-0.0.1.1-4351
- Forums
- ASX - By Stock
- RAC
- RAC media coverage
RAC media coverage, page-2263
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
0.015(0.90%) |
Mkt cap ! $282.8M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.68 | $511 | 305 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 209 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 1213 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 209 | 1.670 |
1 | 22 | 1.665 |
1 | 23 | 1.660 |
3 | 2341 | 1.650 |
1 | 23 | 1.645 |
Price($) | Vol. | No. |
---|---|---|
1.685 | 1213 | 1 |
1.695 | 11124 | 3 |
1.700 | 6382 | 1 |
1.710 | 106 | 1 |
1.720 | 1230 | 2 |
Last trade - 10.22am 05/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |